GENE ONLINE|News &
Opinion
Blog

2022-04-15|

SK Biopharma Teams Up with Targeted Protein Degrader Ubix

by Joy Lin
Share To

SK Biopharmaceuticals has announced that it will collaborate with fellow South Korea biotech Ubix Therapeutics to develop targeted protein degraders against cancer. The news comes as SK Biopharma is looking to expand its CNS and oncology portfolio. 

Under the deal, Ubix will use its Degraducer platform to enable targeted protein degradation while SK Biopharma brings their drug development skills to the table. 

SK Biopharma can opt for exclusive rights to candidates after both companies clear early clinical trials. Ubix will receive an undisclosed upfront payment and milestones, as well as a slice of the profits following commercialization. 

Related Article: Bioplus Interphex 2021: CDMOs- The Manufacturing Hub for the Next Generation of Therapeutics

 

Targeted Protein Degradation 

 

Ubix’s Degraducer technology works by utilizing the ubiquitin-proteasome system, an intracellular degradation system. Candidates are bifunctional molecules consisting of a ligand, which binds the target protein, and a binder that binds to E3 ubiquitin ligase. The molecules bring targets close to the E3 ligase, making ubiquitination much more likely. The ubiquitinated targets are then degraded by the proteasome complex. 

Last June, Ubix partnered with Debiopharm, a Swiss-based biopharma to develop an anti-cancer modality called antibody Degraducer conjugates. The modality combines Ubix’s Degraducer molecule with Debiopharm’s antibody drug conjugate linker and a therapeutic antibody to improve drug targeting and synergy on tumor cells. 

There has been a steady flow of interest and investment in targeted protein degraders. Celeris, a young biotech founded in 2020, recently managed to secure a development contract with Boehringer Ingelheim after a similar deal with Merck (also known as MSD outside the US and Canada). Other companies working in the space include Kymera Therapeutics, Orum Therapeutics and Plexium.

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
R&D
Promising CHIP Protein Could Act as ‘Molecular Switch’ to Longevity
2022-09-21
DeepMind’s AlphaFold Predicts Over 200 Million Protein Shapes in AI Breakthrough
2022-08-01
Why CRY2 matters: Studying Control of Plants and Human Growth
2022-06-20
LATEST
Pfizer’s Q1 2024 Revenue Declines, Offset by Strong Performance of Non-COVID-19 Products
2024-05-03
Novo Nordisk Revises Outlook: Reports 24% Growth in Q1 2024 Sales, Reaching DKK 65.3 Billion
2024-05-03
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
Taiwan Breakthrough: Next-Generation Sequencing Now Covered in Health Insurance, Benefitting 20,000 Cancer Patients Annually
2024-05-02
CellTech Accelerator and Cyto-Facto Inc. Forge Strategic Partnership to Advance CGT Industry Growth
2024-04-29
Kaiser’s Data Breach: 13.4 Million Affected in Healthcare Conglomerates Privacy Crisis
2024-04-26
EVENT
Scroll to Top